Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$28.00 USD
+0.54 (1.97%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $27.98 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Dianthus Therapeutics, Inc. (DNTH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$50.10 | $84.00 | $36.00 | 78.93% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Dianthus Therapeutics, Inc. comes to $50.10. The forecasts range from a low of $36.00 to a high of $84.00. The average price target represents an increase of 82.45% from the last closing price of $27.46.
Analyst Price Targets (10)
Broker Rating
Dianthus Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.10 a month ago based on 10 recommendations.
Of the 11 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90.91% and 9.09% of all recommendations. A month ago, Strong Buy made up 90%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 9 | 9 | 9 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.09 | 1.10 | 1.10 | 1.10 | 1.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/24/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
8/12/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
8/9/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
8/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
8/8/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
7/26/2024 | Robert W. Baird & Co. | Joel L Beatty | Not Available | Strong Buy |
6/27/2024 | Cantor Fitzgerald & Co | Pete Stavropoulos | Not Available | Strong Buy |
6/11/2024 | LifeSci Capital | Rami Katkhuda | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.09 |
ABR (Last week) | 1.10 |
# of Recs in ABR | 11 |
Average Target Price | $50.10 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.59 |
DNTH FAQs
Dianthus Therapeutics, Inc. (DNTH) currently has an average brokerage recommendation (ABR) of 1.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms.
The average price target for Dianthus Therapeutics, Inc. (DNTH) is $50.10. The current on short-term price targets is based on 8 reports.
The forecasts for Dianthus Therapeutics, Inc. (DNTH) range from a low of $36 to a high of $84. The average price target represents a increase of $78.93 from the last closing price of $28.00.
The current UPSIDE for Dianthus Therapeutics, Inc. (DNTH) is 78.93%
Based on short-term price targets offered by 10 analysts, the average price target for Dianthus Therapeutics, Inc. comes to $50.10. The forecasts range from a low of $36.00 to a high of $84.00. The average price target represents an increase of 82.45% from the last closing price of $27.46.